Dermata Therapeutics Inc. (DRMA) is preparing for its first OTC product launch in mid-2026, following a strategic shift from developing prescription dermatology products to focusing on an OTC pharmaceutical product line targeting multiple skin conditions.
The upcoming launch will feature the company's first once-weekly acne treatment kit, under its product line, named Tome, marking a significant step in its expansion into consumer dermatology.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com